This CME-certified enduring activity is jointly provided by
Support for this activity has been provided through an educational grant from AstraZeneca.
The FDA’s approval of several new tailored biologic therapies offers promise to a subset of patients with severe asthma, though identifying the asthma phenotypes (ie, eosinophilic and noneosinophilic) for which these new agents are most appropriate remains a key factor of their successful use.
This CME e-learning Virtual Practice activity provides three modules that discuss the effective use of the newest biologic drugs and address key aspects of successfully assessing and treating patients with severe asthma.
To complete the Virtual Practice, review all content in the Exam Rooms and the Main Conference Room; each room (module) confronts you with challenging clinical scenarios involving patients with severe asthma, similar to those you are likely to encounter in your own practice.
Main Conference Room (Clinical Callout): Here you’ll find four patient vignettes that end at a critical clinical decision point. Your challenge: assess the symptoms, risk factors, and medical histories and choose the most appropriate next step from several possible clinical strategies. But be careful: only one option reflects current best practice!
Exam Room 1: Margaret Thomas, 40, has had asthma for 10 years, but her symptoms have worsened recently and she has experienced two serious exacerbations. Was it a change in her medications? Is it related to her allergies?
Exam Room 2: Al Carter, 55, was first diagnosed with asthma 15 years ago. In the last 3 months, his asthma has been uncontrolled despite the use of oral corticosteroids, and he was hospitalized. Are adjustments needed to Al’s regimen? If so, what are they?
Resource Library: Offers downloadable content discussed in the Virtual Practice.
This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, and primary care providers—including nurse practitioners and physician assistants—who are involved in the treatment of patients with severe asthma.
Upon completion of this activity, participants should be able to:
Discuss the two main types of severe asthma and the treatment implications of each
Discuss the most recent Global Initiative for Asthma (GINA) guidelines for severe asthma treatment (Steps 4/5)
Outline a personalized treatment plan, using targeted biologic therapies, to achieve and maintain control for patients with severe asthma based on underlying phenotype
Demonstrate how incorporating patient education and communication strategies can improve medication adherence and asthma control
Conflict Of Interest Disclosure Policy
According to the disclosure policy of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals who are in a position to control the content of this educational activity are required to disclose to activity participants the existence of any relevant relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of nonprofit or government organizations and non-health care related companies, within the past 12 months. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
Bradley E. Chipps, MD (Program Chair) Medical Director Capital Allergy & Respiratory Disease Center Sacramento, CA
Dr. Chipps has disclosed the following relevant financial relationships: Consultant, Speakers Bureau, and Scientific Advisory Board: AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis Pharmaceuticals, Teva Pharmaceutical Industries
Stephen P. Peters, MD, PhD Thomas H. Davis Chair in Pulmonary Medicine Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases Professor of Internal Medicine, Pediatrics, and Translational Science Wake Forest School of Medicine Executive Director, Respiratory Service Line, Wake Forest Baptist Health Winston-Salem, NC
Dr. Peters has disclosed the following relevant financial relationships: Advisory Boards: Array Biopharma, AstraZeneca, Aerocrine, Airsonett AB, Boehringer Ingelheim, Experts in Asthma, Gilead Sciences, GlaxoSmithKline, Merck, Novartis Pharmaceuticals, Ono Pharmaceuticals, Pfizer, PPD Development, Quintiles, Regeneron Pharmaceuticals, Saatchi & Saatichi, Sanofi, Sunovion Pharmaceuticals, Targacept, Teva Pharmaceutical Industries, Theron Teva Pharmaceutical Basic and Clinical Research: National Heart, Lung, and Blood Institute (Asthma Clinical Research Network, AsthmaNet, Severe Asthma Research Program, SubPopulations and InteRmediate Outcome Measures In COPD Study) Pharmaceutical Trials: Actelion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Centocor, Cephalon, Genentech, GlaxoSmithKline, Forest Laboratories, MedImmune, Sanofi Speakers Bureau: Integrity CE
Michael E. Wechsler, MD, MMSc Co-Director Cohen Family Asthma Institute Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health Denver, CO
Dr. Wechsler has disclosed the following relevant financial relationships: Consultant: AstraZeneca, Boehringer Ingelheim, Boston Scientific, GlaxoSmithKline, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Teva Pharmaceutical Industries, Vectura Group Grant/Research Support: GlaxoSmithKline, Sanofi
Accredited Provider Disclosures
Reviewer Andrew Berman, MD, has disclosed no relevant financial relationships.
Field Testers Peter Rattner, DO, and Jennifer Williams, MD, have disclosed no relevant financial relationships.
Rutgers Biomedical and Health Sciences Center for Continuing Outreach and Education Patrick Dwyer, Director, Continuing Medical Education, has disclosed no relevant financial relationships.
RedMedEd Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships. Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships. Karen Smith, Creative Director, has disclosed no relevant financial relationships. Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships. Barbara Zosh, Director of Operations, has disclosed on relevant financial relationships.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Nurses, Nurses, Physician Assistants
Advanced practice nurses, nurses, and physician assistants may participate in this educational activity and earn a letter of attendance as AANP, ANCC, and AAPA accept AMA PRA Category 1 CreditsTM through their reciprocity agreements.
To help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences (RBHS) has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by:
Andrew Berman, MD, Professor of Medicine, Director, Division of Pulmonary and Critical Care Medicine/Allergy and Immunologic Diseases, Rutgers New Jersey Medical School, Newark, New Jersey.
This activity was pilot-tested for time required for participation by Peter Rattner, DO and Jennifer Williams, MD.
Disclosure of Unlabled Use
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RBHS and RedMedEd do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any manufacturer of pharmaceuticals or devices, Rutgers Biomedical and Health Sciences, or RedMedEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Clicking "START ACTIVITY" will send you away from myCME to our partner site, RedMedEd. Full accreditation/designation and disclosure information will be provided on the RedMedEd site.
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the post-tests (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately and will not be stored in your myCME CME History.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or firstname.lastname@example.org.
For questions regarding the activity content, or CME-related questions or concerns, contact RBHS at (973) 972-4267 or email@example.com.
Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
A computer with an Internet connection
Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required